Late on Monday, the 28th of October 2019, the UN (United Nations)-backed Stop TB Partnership had issued a statement saying that a newly approved $1,040 three-drug combination therapy for tuberculosis, a disease responsible for more than 1.5 million deaths in 2018, would soon be available in more than 150 countries including South Africa alongside India, however, the expense was more than twice the cost proposed earlier by an advocacy groups for other treatments.
On top of that, the STOP TB Partnership had added in its Monday’s (October 28th) statement that its new three-drug oral therapy consisted of TB Alliance’s pretomanid in combination with linezolid and Johnson & Johnson’s bedaquiline, also dubbed as BPaL, could be obtained in the eligible countries through the Global Drug Facility, a global provider of low-cost medicines founded back in 2001 in order to negotiate lower prices of treatments.
Since the new treatment regimen for tuberculosis, BPaL, an oral combination therapy consisted of Pretomanid, bedaquiline and linezolid showed efficacy against the most-extensive drug-resistant strains of tuberculosis, industry analysts had called it as a promising oral treatment for drug-resistant tuberculosis or relapse, offering a shorter alongside a more convenient option, which might not be achieved using currently available fixed-dose combination of Rimactazid (Isoniazid and Rifampicin) alongside Pyrazinamide, Ethambutol and Streptomycin.
Besides, under the new TB treatment, the drugs would be offered in bottles of 26 tables, while a seven-month treatment regimen would require seven bottles. Aside from that, an India-based pharmaceutical, Macleods Pharmaceuticals Ltd.
was also granted a license to manufacture pretomanid as part of BPaL regimen, nonetheless the generic drug maker would likely to market the drug in more than 140 countries at a higher rate, a source said.